Last updated on August 2019

Safety Tolerability Pharmacokinetics and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease


Brief description of study

The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS-MAPTRx in patients with Mild Alzheimer's Disease

Detailed Study Description

This is a randomized, double-blind, placebo-controlled study, followed by an Open-Label Extension in up to 44 participants. This study will consist in two parts:

Part 1: a randomized, double-blind, placebo-controlled multiple ascending dose period in participants with Mild Alzheimer's Disease, followed by Part 2: the open-label, long-term extension period.

Clinical Study Identifier: NCT03186989

Find a site near you

Start Over

QPS Netherlands BV

Groningen, Netherlands
  Connect »